N-tert-butylmethylprolinol | 75041-82-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: N-tert-butylmethylprolinol
• 英文别名: (-)-(2S)-N-(2,2-dimethylpropyl)pyrrolidine-2-methanol；[(2S)-1-(2,2-Dimethylpropyl)pyrrolidin-2-yl]methanol
• CAS: 75041-82-6
• 化学式: C₁₀H₂₁NO
• 分子量: 171.283
• InChiKey: HPYDVQQTWXLJNN-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-tert-butylmethylprolinol 在 sodium hydroxide 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 27.0h， 生成 (-)-(3R)-1-(2,2-dimethylpropyl)piperidin-3-ol
  参考文献：
  名称：

  扩环 – 从吡咯烷甲醇衍生物形成光学活性 3-羟基哌啶

  摘要：

  用三氟乙酸处理吡咯烷甲醇衍生物 (–)-1、(–)-6、(–)-7、8、(–)-9、(+)-10、(–)-11 和 (–)-21酸酐，然后用 Et3N，在三氟乙酰基用 NaOH 水解后，得到旋光 3-羟基哌啶 (-)-14, (+)-15, (-)-16, 17, (+)-18, (- )-19、(–)-20 和 (+)-22 分别。产率良好，对映体过量非常好（高达 95%）。

  DOI：

  10.1002/(sici)1099-0690(199907)1999:7<1693::aid-ejoc1693>3.0.co;2-j
• 作为产物：
  描述：

  (2R,5S)-2-tert-butyl-1-aza-3-oxabicyclo[3.3.0]octan-4-one 在 lithium aluminium tetrahydride 作用下， 生成 N-tert-butylmethylprolinol
  参考文献：
  名称：

  形成光学活性的3-羟基哌啶

  摘要：

  对映体纯的3-羟基哌啶已由脯氨醇合成。

  DOI：

  10.1016/0040-4039(94)02338-c

文献信息

• Ring Expansion Induced by DAST: Synthesis of Substituted 3-Fluoropiperidines from Prolinols and 3-Fluoroazepanes from 2-Hydroxymethylpiperidines
  作者：Ingrid Déchamps、Domingo Gomez Pardo、Janine Cossy

  DOI：10.1002/ejoc.200700237

  日期：2007.9

  Optically active prolinols can be converted into optically active 3-fluoropiperidines by treatment with DAST. The reaction often produces 2-fluoromethylpyrrolidines as byproducts. The ring expansion was also applied to 2-hydroxypiperidines to produce 3-fluoroazepanes. The rearrangement proceeds via an aziridinium intermediate. (© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2007)

  光学活性脯氨醇可以通过 DAST 处理转化为光学活性 3-氟哌啶。该反应通常会产生 2-氟甲基吡咯烷作为副产物。扩环也适用于 2-羟基哌啶以产生 3-氟氮杂环庚烷。重排通过氮丙啶中间体进行。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2007)
• Synthesis of Optically Active Substituted 3-Fluoropiperidines from Prolinols by Using DAST
  作者：Janine Cossy、Ingrid Déchamps、Domingo Gomez Pardo

  DOI：10.1055/s-2007-967989

  日期：2007.2

  The treatment of optically active prolinols with DAST produces optically active 3-fluoropiperidines via aziridinium intermediates.

  用 DAST 处理具有光学活性的脯氨醇，可通过氮丙啶中间体生成具有光学活性的 3-氟哌啶。
• New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds
  申请人：Roth Juergen Gerald

  公开号：US20070111981A1

  公开（公告）日：2007-05-17

  The present invention relates to (hetero)aryl compounds of general formula I wherein the groups and radicals A, B, Q, W, X, Y, Z, R 1 , R 2 , R 4a , R 4b , R 5a , R 5b , have the meanings given in claim 1 . Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I的（杂）芳基化合物，其中A、B、Q、W、X、Y、Z、R1、R2、R4a、R4b、R5a和R5b基团和基团具有权利要求1中给出的含义。此外，本发明涉及至少含有本发明中的一种化合物的制药组合物。由于其MCH受体拮抗活性，根据本发明的制药组合物适用于治疗代谢紊乱和/或进食障碍，尤其是肥胖症、贪食症、厌食症、暴食症和糖尿病。
• LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT
  申请人：Wakiyama Yoshinari

  公开号：US20100210570A1

  公开（公告）日：2010-08-19

  An objective of the present invention is to provide compounds of formula (1) or their pharmacologically acceptable salts or solvates wherein A represents aryl; R 1 represents N-optionally substituted C 1-6 alkyl-N-optionally substituted C 1-6 alkylamino-C 1-6 alkyl; R 2 represents a hydrogen atom or optionally substituted C 1-6 alkyl; R 3 represents optionally substituted C 1-6 alkyl or C 3-6 cycloalkyl-C 1-4 alkyl; m is 1 to 3; n is 0; and p is 0 to 2. The compounds are novel lincomycin derivatives that have a potent activity against resistant Streptococcus pneumoniae, which have recently posed problems, in the treatment of infectious diseases. Further, the compounds are usable as antimicrobial agents and are useful for preventing or treating bacterial infectious diseases.

  本发明的目标是提供以下化合物(1)或其药理学上可接受的盐或溶剂，其中A代表芳基；R1代表N-可选取代的C1-6烷基-N-可选取代的C1-6烷基氨基-C1-6烷基；R2代表氢原子或可选取代的C1-6烷基；R3代表可选取代的C1-6烷基或C3-6环烷基-C1-4烷基；m为1至3；n为0；p为0至2。这些化合物是新颖的林可霉素衍生物，对最近在感染性疾病治疗中引起问题的耐药性肺炎链球菌具有强效活性。此外，这些化合物可用作抗微生物药物，有助于预防或治疗细菌感染性疾病。
• Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds
  申请人：Lehmann-Lintz Thorsten

  公开号：US20100197908A1

  公开（公告）日：2010-08-05

  The present invention relates to compounds of general formula I wherein the groups and radicals B, W, X, Y, Z, R 1 , R 2 , have the meanings given in claim 1 . Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I的化合物，其中基团和基团B、W、X、Y、Z、R1、R2的含义如权利要求书1所述。此外，本发明还涉及含有本发明中至少一种化合物的制药组合物。由于其MCH受体拮抗活性，本发明中的制药组合物适用于治疗代谢性疾病和/或饮食障碍，特别是肥胖症、暴食症、厌食症、暴食症和糖尿病。